FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3167939738> ?p ?o ?g. }

• W3167939738 endingPage "1167.e3" @default.
• W3167939738 startingPage "1156" @default.
• W3167939738 abstract "VARSITY (An Efficacy and Safety Study of Vedolizumab Intravenous [IV] Compared to Adalimumab Subcutaneous [SC] in Participants With Ulcerative Colitis) showed superior clinical remission and endoscopic improvement in ulcerative colitis with vedolizumab vs adalimumab. This analysis compared histologic outcomes.Patients in VARSITY were randomized 1:1 to maintenance with vedolizumab IV 300 mg every 8 weeks or adalimumab SC 40 mg every 2 weeks (both following standard induction). Geboes Index and Robarts Histopathology Index (RHI) scores were used to assess prespecified histologic exploratory end points of histologic remission (Geboes <2 or RHI ≤2) and minimal histologic disease activity (Geboes ≤3.1 or RHI ≤4) at weeks 14 and 52.In total, 769 patients received vedolizumab (n = 383) or adalimumab (n = 386). Mean baseline histologic disease activity was similar between vedolizumab and adalimumab groups. Vedolizumab induced greater histologic remission than adalimumab at week 14 (Geboes: 16.7% vs 7.3%, Δ9.4% [95% confidence interval {CI}, 4.9%-13.9%], P < .0001; RHI: 25.6% vs 16.1%, Δ9.5% [95% CI, 3.8%-15.2%], P = .0011) and week 52 (Geboes: 29.2% vs 8.3%, Δ20.9% [95% CI, 15.6%-26.2%], P < .0001; RHI: 37.6% vs 19.9%, Δ17.6% [95% CI, 11.3%-23.8%], P < .0001) overall and in both anti-tumor necrosis factor (TNF)-naïve and -failure subgroups. Results were similar for minimal histologic disease activity. Histologic outcomes were generally better in anti-TNF-naïve vs -failure patients. At week 52, rates of mucosal healing (composite end point of histologic plus endoscopic improvement) were also higher with vedolizumab than adalimumab (Geboes: 25.6% vs 6.7%; RHI: 30.5% vs 14.5%).Higher rates of histologic remission, minimal histologic disease activity, and combined histologic plus endoscopic outcomes were observed with vedolizumab than with adalimumab in ulcerative colitis in both anti-TNF-naïve and -failure subgroups.ClinicalTrials.gov NCT02497469; EudraCT 2015-000939-33." @default.
• W3167939738 created "2021-06-22" @default.
• W3167939738 creator A5015470174 @default.
• W3167939738 creator A5017140014 @default.
• W3167939738 creator A5042884495 @default.
• W3167939738 creator A5046814722 @default.
• W3167939738 creator A5051743242 @default.
• W3167939738 creator A5054528938 @default.
• W3167939738 creator A5059435501 @default.
• W3167939738 creator A5066649201 @default.
• W3167939738 creator A5068806006 @default.
• W3167939738 creator A5087619596 @default.
• W3167939738 date "2021-10-01" @default.
• W3167939738 modified "2023-10-18" @default.
• W3167939738 title "Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY)" @default.
• W3167939738 cites W1492282569 @default.
• W3167939738 cites W1929766967 @default.
• W3167939738 cites W1964102710 @default.
• W3167939738 cites W1974246098 @default.
• W3167939738 cites W2057141381 @default.
• W3167939738 cites W2094436918 @default.
• W3167939738 cites W2110052276 @default.
• W3167939738 cites W2116318925 @default.
• W3167939738 cites W2125255283 @default.
• W3167939738 cites W2149170290 @default.
• W3167939738 cites W2152790886 @default.
• W3167939738 cites W2296988598 @default.
• W3167939738 cites W2306466871 @default.
• W3167939738 cites W2555002243 @default.
• W3167939738 cites W2589294144 @default.
• W3167939738 cites W2598413495 @default.
• W3167939738 cites W2783177521 @default.
• W3167939738 cites W2888572800 @default.
• W3167939738 cites W2911317352 @default.
• W3167939738 cites W2919081348 @default.
• W3167939738 cites W2976731348 @default.
• W3167939738 cites W3033901345 @default.
• W3167939738 cites W3115410759 @default.
• W3167939738 cites W3131102858 @default.
• W3167939738 cites W4210662453 @default.
• W3167939738 doi "https://doi.org/10.1053/j.gastro.2021.06.015" @default.
• W3167939738 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34144047" @default.
• W3167939738 hasPublicationYear "2021" @default.
• W3167939738 type Work @default.
• W3167939738 sameAs 3167939738 @default.
• W3167939738 citedByCount "15" @default.
• W3167939738 countsByYear W31679397382021 @default.
• W3167939738 countsByYear W31679397382022 @default.
• W3167939738 countsByYear W31679397382023 @default.
• W3167939738 crossrefType "journal-article" @default.
• W3167939738 hasAuthorship W3167939738A5015470174 @default.
• W3167939738 hasAuthorship W3167939738A5017140014 @default.
• W3167939738 hasAuthorship W3167939738A5042884495 @default.
• W3167939738 hasAuthorship W3167939738A5046814722 @default.
• W3167939738 hasAuthorship W3167939738A5051743242 @default.
• W3167939738 hasAuthorship W3167939738A5054528938 @default.
• W3167939738 hasAuthorship W3167939738A5059435501 @default.
• W3167939738 hasAuthorship W3167939738A5066649201 @default.
• W3167939738 hasAuthorship W3167939738A5068806006 @default.
• W3167939738 hasAuthorship W3167939738A5087619596 @default.
• W3167939738 hasConcept C126322002 @default.
• W3167939738 hasConcept C141071460 @default.
• W3167939738 hasConcept C17991360 @default.
• W3167939738 hasConcept C2776207728 @default.
• W3167939738 hasConcept C2778260677 @default.
• W3167939738 hasConcept C2779134260 @default.
• W3167939738 hasConcept C2780132546 @default.
• W3167939738 hasConcept C2780479503 @default.
• W3167939738 hasConcept C71924100 @default.
• W3167939738 hasConcept C90924648 @default.
• W3167939738 hasConceptScore W3167939738C126322002 @default.
• W3167939738 hasConceptScore W3167939738C141071460 @default.
• W3167939738 hasConceptScore W3167939738C17991360 @default.
• W3167939738 hasConceptScore W3167939738C2776207728 @default.
• W3167939738 hasConceptScore W3167939738C2778260677 @default.
• W3167939738 hasConceptScore W3167939738C2779134260 @default.
• W3167939738 hasConceptScore W3167939738C2780132546 @default.
• W3167939738 hasConceptScore W3167939738C2780479503 @default.
• W3167939738 hasConceptScore W3167939738C71924100 @default.
• W3167939738 hasConceptScore W3167939738C90924648 @default.
• W3167939738 hasFunder F4320333965 @default.
• W3167939738 hasIssue "4" @default.
• W3167939738 hasLocation W31679397381 @default.
• W3167939738 hasLocation W31679397382 @default.
• W3167939738 hasOpenAccess W3167939738 @default.
• W3167939738 hasPrimaryLocation W31679397381 @default.
• W3167939738 hasRelatedWork W2006826205 @default.
• W3167939738 hasRelatedWork W2033059461 @default.
• W3167939738 hasRelatedWork W2042655884 @default.
• W3167939738 hasRelatedWork W2802577932 @default.
• W3167939738 hasRelatedWork W2913273475 @default.
• W3167939738 hasRelatedWork W2923211281 @default.
• W3167939738 hasRelatedWork W2976731348 @default.
• W3167939738 hasRelatedWork W3028093540 @default.
• W3167939738 hasRelatedWork W3167939738 @default.
• W3167939738 hasRelatedWork W3199295110 @default.
• W3167939738 hasVolume "161" @default.
• W3167939738 isParatext "false" @default.

• next